Cogent Biosciences, Inc.
Clinical trials sponsored by Cogent Biosciences, Inc., explained in plain language.
-
New pill targets hard-to-treat bile duct cancers with gene mutations
Disease control OngoingThis study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have certain genetic changes (FGFR2 or FGFR3). The goal is to find the best dose and see if the drug can shrink tumors or slow their growth. About 110 adults w…
Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New combo therapy aims to slow Tough-to-Treat gut tumors
Disease control OngoingThis study tests whether adding the experimental drug CGT9486 to the standard drug sunitinib works better than sunitinib alone for people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery or have spread. About 482 adults who have already tried …
Phase: PHASE3 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 07:50 UTC
-
New hope for mastocytosis patients: drug trial targets debilitating symptoms
Symptom relief OngoingThis study tests an experimental drug called bezuclastinib (CGT9486) in adults with nonadvanced systemic mastocytosis, a condition where too many mast cells cause symptoms like flushing, itching, and stomach issues. About 237 participants will receive either the drug or a placebo…
Phase: PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Symptom relief
Last updated May 26, 2026 07:25 UTC